14898-52-3

Usage

Synthesis Reference(s)

Tetrahedron, 50, p. 8099, 1994 DOI: 10.1016/S0040-4020(01)85292-3

InChI:InChI=1/C10H13NO2/c1-13-10(12)7-9(11)8-5-3-2-4-6-8/h2-6,9H,7,11H2,1H3

Upstream product

• 67-56-1 methanol 
• 53030-50-5 3-amino-3-phenyl-DL-propionyl chloride 
• 3646-50-2 3-Amino-3-phenylpropionic acid 
• 614-27-7 methyl 3-oxo-3-phenylpropionate 
• 100-52-7 benzaldehyde 
• 257861-50-0 3-tert-butoxycarbonylamino-3-phenylpropionic acid methyl ester 
• 223660-69-3 methyl 3-(2-methoxyphenyl)amino-3-phenylpropionate 
• 52341-70-5 N-chlorosulfonyl-4-phenylazetidin-2-one 
• 124-41-4 sodium methylate 
• 32493-34-8 methyl 3‐((methoxysulfonyl)amino)‐3‐phenylpropanoate 
• 22838-46-6 methyl 3-amino-3-phenylpropionate hydrochloride 
• 103-25-3 3-phenylpropanoic acid methyl ester 
• 141-82-2 malonic acid 
• 157371-84-1 1-Phenyl-2-(2,4,10-trioxa-tricyclo[3.3.1.1^3,7]dec-3-yl)-ethanone oxime 

Downstream Products

• 73786-49-9 1,2-dihydro-2-phenyl-3-methoxycarbonyl-5,6-bis(tert-butylthio)pyridine 
• 5661-55-2 4-phenylazetidin-2-one 
• 37088-66-7 (3S)-methyl 3-amino-3-phenylpropanoate 
• 180264-40-8 N-methyl-3-amino-3-phenylpropionamide 
• 403600-03-3 (R,S)-methyl 3-{3-[6-(3-benzylureido)indolin-1-yl]-3-oxopropanoylamino}-3-phenylpropanoate 
• 103-26-4 Methyl cinnamate 
• 656808-19-4 (RS)-(+/-)-N-(2-(methoxycarbonyl)-1-phenylethyl)malonamic acid methyl ester 
• 439089-08-4 1,1-Dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-(α-methoxycarbonylmethyl-benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine 
• 1073697-37-6 3-(naphthyl-2-sulfonamido)-3-phenylpropionic acid methyl ester 
• 1228293-50-2 C₃₃H₄₁NO₇ 
• 1243990-24-0 C₂₈H₃₅N₃O₆ 
• 887274-83-1 1-{3-[(3-methoxy-3-oxo-1-phenylpropyl)amino]-2-nitrophenyl}-4-piperidinecarboxylic acid 
• 614-19-7 (R)-3-phenyl-3-aminopropionic acid 
• 614-19-7 (S)-3-amino-3-phenylpropanoic acid 

Relevant academic research and scientific papers

β-Amino esters via the Reformatsky reaction: Restraining effects of the ortho-methoxyphenyl substituent

β-Amino esters are, in most cases, the only products of the Reformatsky reaction in CH2Cl2 between (methoxycarbonyl)methyl zinc bromide (prepared in-situ) and imines prepared from either an aryl or alkyl aldehyde and o- anisdine (Sch

Transition Metal-Free N-Arylation of Amino Acid Esters with Diaryliodonium Salts

A transition metal-free approach for the N-arylation of amino acid derivatives has been developed. Key to this method is the use of unsymmetric diaryliodonium salts with anisyl ligands, which proved important to obtain high chemoselectivity and yields. The scope includes the transfer of both electron deficient, electron rich and sterically hindered aryl groups with a variety of different functional groups. Furthermore, a cyclic diaryliodonium salt was successfully employed in the arylation. The N-arylated products were obtained with retained enantiomeric excess.

Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity

Crystal structures of ligand-bound G-protein-coupled receptors provide tangible templates for rationally designing molecular probes. Herein, we report the structure-based design, chemical synthesis, and biological investigations of bivalent ligands targeting putative mu opioid receptor C-C motif chemokine ligand 5 (MOR-CCR5) heterodimers. The bivalent ligand VZMC013 possessed nanomolar level binding affinities for both the MOR and CCR5, inhibited CCL5-stimulated calcium mobilization, and remarkably improved anti-HIV-1BaL activity over previously reported bivalent ligands. VZMC013 inhibited viral infection in TZM-bl cells coexpressing CCR5 and MOR to a greater degree than cells expressing CCR5 alone. Furthermore, VZMC013 blocked human immunodeficiency virus (HIV)-1 entry in peripheral blood mononuclear cells (PBMC) cells in a concentration-dependent manner and inhibited opioid-accelerated HIV-1 entry more effectively in phytohemagglutinin-stimulated PBMC cells than in the absence of opioids. A three-dimensional molecular model of VZMC013 binding to the MOR-CCR5 heterodimer complex is constructed to elucidate its mechanism of action. VZMC013 is a potent chemical probe targeting MOR-CCR5 heterodimers and may serve as a pharmacological agent to inhibit opioid-exacerbated HIV-1 entry.

Carbon Dioxide-Mediated C(sp2)-H Arylation of Primary and Secondary Benzylamines

C-C bond formation by transition metal-catalyzed C-H activation has become an important strategy to fabricate new bonds in a rapid fashion. Despite the pharmacological importance of ortho-arylbenzylamines, however, effective ortho-C-C bond formation of free primary and secondary benzylamines using PdII remains an outstanding challenge. Presented herein is a new strategy for constructing ortho-arylated primary and secondary benzylamines mediated by carbon dioxide (CO2). The use of CO2 with Pd is critical to allowing this transformation to proceed under relatively mild conditions, and mechanistic studies indicate that it (CO2) is directly involved in the rate-determining step. Furthermore, the milder temperatures furnish free amine products that can be directly used or elaborated without the need for deprotection. In cases where diarylation is possible, an interesting chelate effect is shown to facilitate selective monoarylation.

Intermolecular Radical C(sp3)?H Amination under Iodine Catalysis

The direct amination of aliphatic C?H bonds has remained one of the most tantalizing transformations in organic chemistry. Herein, we report on a unique catalyst system, which enables the elusive intermolecular C(sp3)?H amination. This practical synthetic strategy provides access to aminated building blocks and fosters innovative multiple C?H amination within a new approach to aminated heterocycles. The synthetic utility is demonstrated by the synthesis of four relevant pharmaceuticals.

Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer

Eukaryotic elongation factor 2 kinase (eEF2K) is a Ca2+/calmudulin-dependent protein kinase, belonging to a small family of an atypical Ser/Thr-protein kinase. eEF2K has been recently reported to be highly activated or overexpressed in many types of cancer; therefore, eEF2K would be regarded as a promising therapeutic target. In this study, we discovered a β-phenylalanine scaffold by virtual high-throughput screening, as well as designed and synthesized 46 derivatives with assessment of inhibition activity against eEF2K and cytotoxicity. After several rounds of kinase and anti-proliferative activity screening, we discovered an eEF2K inhibitor (21l) with best eEF2K enzymatic activity (IC50 of 5.5 μM) and anti-proliferative activity (MDA-MB-231 cells, IC50 of 12.6 μM, MDA-MB-436 cells, IC50 of 19.8 μM). Moreover, we found that 21l could induce cell death via the apoptotic pathways in MDA-MB-231 and MDA-MB-436 cells. Subsequently, we evaluated its anti-tumor activity and apoptosis-inducing mechanisms in vivo. These results suggested that 21l inhibited tumor growth by apoptosis in the xenograft mouse model of breast cancer (MDA-MB-231 and MDA-MB-436). Collectively, our results demonstrate a novel small-molecule inhibitor targeting eEF2K with mechanism of apoptosis and a therapeutic potential in breast cancer.

Preparation and application of novel eEF2K depressant

The invention relates to preparation and application of an eEF2K depressant and belongs to the technical field of antitumor pharmacy. A technical problem to be solved by the invention is to provide acompound as the eEF2K depressant. The compound comprises a compound represented by a formula shown in the description or pharmaceutically acceptable salts thereof. The compound or pharmaceutically acceptable salts thereof can serve as the eEF2K depressant, have certain anti-tumor activity and can effectively depress the growth of cancer cells. The compound disclosed by the invention has an obviousdepression action on a variety of tumor cells, particularly three-negative mammary cancer cells.

HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxamides as described herein, useful as histone demethyiase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

HETEROARYL-CARBOXYLIC ACIDS AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxylic acids as described herein, useful as histone demethylase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors

Epidermal growth factor receptor inhibitors are of importance in cancer therapy and possibly in the management of pain. Herein, we report a structure-activity relationship study with 29 new 6-aryl-furo[2,3-d]pyrimidin-4-amines, involving modification of the 4-amino group and 6-aryl function. The EGFR activity was especially dependent on having a chiral 4-benzylamino group with correct stereochemistry. Molecular dynamics indicate this to be due to favourable cation-π interactions. The most active inhibitor identified, equipotent to Erlotinib, was substituted with (R)-1-phenylethylamine at C-4 and a N1, N1-dimethyl-1,2-diamine group in para position of the 6-aryl moiety. These new furopyrimidines had a different off-target kinase profile when compared to Erlotinib, and also possessed high activity towards Ba/F3 EGFRL858R reporter cells. Further, comparing the EGFR data of the furo[2,3-d]pyrimidin-4-amines with that of the corresponding thieno- and pyrrolopyrimidines concludes the furopyrimidine scaffold to be highly useful for development of new epidermal growth factor receptor antagonists.